# Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

> **NCT02949193** · PHASE3 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 222 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** evogliptin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT02949193
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-11
- **Final completion:** 2015-05
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949193, "Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02949193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*